Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Senkus E, Łacko A. Over-treatment in metastatic breast cancer. Breast. 2017;31:309–317. doi:10.1016/j.breast.2016.06.024
   PubMed Web of Science ®Google Scholar
• Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20(11):3469–3476. doi:10.1245/s10434-013-3011-9
   PubMed Web of Science ®Google Scholar
• van Maaren MC, de Munck L, Strobbe LJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144(2):263–272. doi:10.1002/ijc.31914
   PubMed Web of Science ®Google Scholar
• Cipora E, Konieczny M, Karwat ID, et al. Surgical method of treatment and level of satisfaction with life among women diagnosed with breast cancer, according to time elapsed since performance of surgery. Ann Agric Environ Med. 2018;25(3):453–459. doi:10.26444/aaem/91586
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Breast cancer. National Comprehensive Cancer Network: National Clinical Practice Guidelines in Oncology. Version 2; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed October 13, 2023.
   Google Scholar
• Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–933.
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–926. doi:10.1001/jama.2017.11470
   PubMed Web of Science ®Google Scholar
• Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. doi:10.1016/S1470-2045(14)70460-7
   PubMed Web of Science ®Google Scholar
• Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, Phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672–679. doi:10.1016/j.ejso.2016.12.011
   PubMed Web of Science ®Google Scholar
• Wilson RE. Surgical management of locally advanced and recurrent breast cancer. Cancer. 1984;53(3 Suppl):752–757.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355(9217):1757–1770. doi:10.1016/S0140-6736(00)02263-7
   PubMed Web of Science ®Google Scholar
• Donegan WL, Perez-Mesa CM, Watson FR. A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet. 1966;122(3):529–540.
   PubMedGoogle Scholar
• Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1990;19(4):851–858. doi:10.1016/0360-3016(90)90004-4
   PubMed Web of Science ®Google Scholar
• Mano MS, Awada A. Primary chemotherapy for breast cancer: the evidence and the future. Ann Oncol. 2004;15(8):1161–1171. doi:10.1093/annonc/mdh302
   PubMed Web of Science ®Google Scholar
• Moo TA, Sanford R, Dang C, et al. Overview of breast cancer therapy. PET Clin. 2018;13(3):339–354. doi:10.1016/j.cpet.2018.02.006
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785. doi:10.1200/JCO.2007.15.0235
   PubMed Web of Science ®Google Scholar
• Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94(10):1189–1200. doi:10.1002/bjs.5894
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-8
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa1804710
   PubMed Web of Science ®Google Scholar
• Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. J Clin Oncol. 2019;37(22):1956–1964. doi:10.1200/JCO.19.00945
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647–2655. doi:10.1200/JCO.2016.71.4147
   PubMed Web of Science ®Google Scholar
• Nitz U, Gluz O, Clemens M, et al. West German Study Plan B Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019;37(10):799–808. doi:10.1200/JCO.18.00028
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497–1508. doi:10.1093/annonc/mdy127
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–756. doi:10.1016/S1470-2045(14)70160-3
   PubMed Web of Science ®Google Scholar
• Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a Phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390–1396. doi:10.1001/jamaoncol.2020.2965
   PubMed Web of Science ®Google Scholar
• Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325(1):50–58. doi:10.1001/jama.2020.23370
   PubMed Web of Science ®Google Scholar
• Parsons HA, Burstein HJ. Adjuvant capecitabine in triple-negative breast cancer: new strategies for tailoring treatment recommendations. JAMA. 2021;325(1):36–38. doi:10.1001/jama.2020.23371
   PubMed Web of Science ®Google Scholar
• Downing A, Twelves C, Forman D, et al. Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J. 2014;20(1):29–36. doi:10.1111/tbj.12209
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, et al. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2016;2(3):322–329. doi:10.1001/jamaoncol.2015.3856
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–1439. doi:10.1200/JCO.2003.09.081
   PubMed Web of Science ®Google Scholar
• Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–2387. doi:10.1200/JCO.2012.45.2615
   PubMed Web of Science ®Google Scholar
• Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–273. doi:10.1016/S1470-2045(14)71221-5
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–520. doi:10.1056/NEJMoa0906260
   PubMed Web of Science ®Google Scholar
• Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–1094. doi:10.1016/S1470-2045(13)70386-3
   PubMed Web of Science ®Google Scholar
• Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015):229–238. doi:10.1016/S0140-6736(15)00471-7
   PubMed Web of Science ®Google Scholar
• Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048–1060. doi:10.1016/S0140-6736(17)31145-5
   PubMed Web of Science ®Google Scholar
• Marta GN, Macedo CR, Carvalho Hde A, et al. Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiother Oncol. 2015;114(1):42–49. doi:10.1016/j.radonc.2014.11.014
   PubMed Web of Science ®Google Scholar
• Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269–1277. doi:10.1016/S1470-2045(13)70497-2
   PubMed Web of Science ®Google Scholar
• Kwong DL, McGale P, Taylor C, et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–2135. doi:10.1016/S0140-6736(14)60488-8
   PubMed Web of Science ®Google Scholar
• McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89(2):392–398. doi:10.1016/j.ijrobp.2014.02.013
   PubMed Web of Science ®Google Scholar
• Muhsen S, Moo TA, Patil S, et al. Most breast cancer patients with T1–2 tumors and one to three positive lymph nodes do not need postmastectomy radiotherapy. Ann Surg Oncol. 2018;25(7):1912–1920. doi:10.1245/s10434-018-6422-9
   PubMed Web of Science ®Google Scholar
• Wu SG, Wang J, Lian CL, et al. Evaluation of the 8th edition of the American joint committee on cancer’s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy. Breast. 2020;51:2–10. doi:10.1016/j.breast.2020.02.012
   PubMed Web of Science ®Google Scholar
• Wang S, Wen G, Tang Y, et al. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions. BMC Cancer. 2020;20(1):792. doi:10.1186/s12885-020-07267-5
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–316. doi:10.1056/NEJMoa1415340
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supra-clavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–327. doi:10.1056/NEJMoa1415369
   PubMed Web of Science ®Google Scholar
• Thorsen LBJ, Offersen BV, Dano H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34(4):314–320. doi:10.1200/JCO.2015.63.6456
   PubMed Web of Science ®Google Scholar
• Hennequin C, Bossard N, Servagi-Vernat S, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86(5):860–866. doi:10.1016/j.ijrobp.2013.03.021
   PubMed Web of Science ®Google Scholar
• Du L, Yau C, Brown-Swigart L, et al. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol. 2021;32(5):642–651. doi:10.1016/j.annonc.2021.02.011
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J. Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: a TLAS, a randomised trial. Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–118. doi:10.1056/NEJMoa1404037
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–446. doi:10.1056/NEJMoa1412379
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352. doi:10.1016/S0140-6736(15)61074-1
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–518. doi:10.1200/JCO.2009.23.1274
   PubMed Web of Science ®Google Scholar
• Knauer M, Filipits M, Dubsky P. Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial? Breast Care. 2014;9(2):97–100. doi:10.1159/000362482
   PubMed Web of Science ®Google Scholar
• Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21(2):250–260. doi:10.1016/S1470-2045(19)30804-6
   PubMed Web of Science ®Google Scholar
• Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–3074. doi:10.1093/annonc/mds132
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative Anastrozole, Tamoxifen, or combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–5116. doi:10.1200/JCO.2005.04.005
   PubMed Web of Science ®Google Scholar
• Horobin JM, Preece PE, Dewar JA, et al. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78(2):213–217. doi:10.1002/bjs.1800780228
   PubMed Web of Science ®Google Scholar
• Gaskell DJ, Hawkins RA, de Carteret S, et al. Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg. 1992;79(12):1317–1320. doi:10.1002/bjs.1800791225
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Guo H, et al. Seven-year follow-up of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2+ breast cancer. J Clin Oncol. 2017;35(15 suppl):511. doi:10.1200/JCO.2017.35.15_suppl.511
   Google Scholar
• Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a Phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646–653. doi:10.1093/annonc/mdx773
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi:10.1016/S1470-2045(11)70336-9
   PubMed Web of Science ®Google Scholar
• Fernandez-Martinez A, Krop IE, Hillman DW, et al. Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J Clin Oncol. 2020;38(35):4184–4193. doi:10.1200/JCO.20.01276
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 2020;38(27):3138–3149. doi:10.1200/JCO.20.00147
   PubMed Web of Science ®Google Scholar
• Smyth LM, Piha-Paul SA, Won HH, et al. Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer. Cancer Discov. 2020;10(2):198–213. doi:10.1158/2159-8290.CD-19-0966
   PubMed Web of Science ®Google Scholar
• Warwas KM, Meyer M, Gonçalves M, et al. Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models. Front Immunol. 2021;12:719116. doi:10.3389/fimmu.2021.719116
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80. doi:10.1126/science.aaa6204
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–2467. doi:10.1200/JCO.2015.64.8931
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404. doi:10.1093/annonc/mdy517
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671–686. doi:10.1007/s10549-017-4537-5
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Kalinsky K, Kaklamani V, et al. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer [abstract]. Cancer Res. 2018;78(Suppl):PD6–PD13. doi:10.1158/1538-7445.SABCS17-PD6-13
   Google Scholar
• Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 2019;5:334–342. doi:10.1001/jamaoncol.2018.5152
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. doi:10.1016/S1470-2045(19)30689-8
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004. doi:10.1016/j.annonc.2021.05.801
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9
   PubMed Web of Science ®Google Scholar
• Loi S, Giobbie-Hurder A, Gombos A, et al; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20(3):371–382. doi:10.1016/S1470-2045(18)30812-X
   PubMed Web of Science ®Google Scholar
• Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–1295. doi:10.1016/S1470-2045(20)30465-4
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684. doi:10.1001/jamaoncol.2019.6650
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. KEYNOTE-522: phase 3 study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo (pbo) 1 chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment of early triple-negative breast cancer (TNBC). Ann Oncol. 2019;30(Suppl 5):v851–v934. doi:10.1093/annonc/mdz394.003
   Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288. doi:10.1093/annonc/mdz158
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100. doi:10.1016/S0140-6736(20)31953-X
   PubMed Web of Science ®Google Scholar
• Dastjerd NT, Valibeik A, Rahimi Monfared S, et al. Gene therapy: a promising approach for breast cancer treatment. Cell Biochem Funct. 2022;40(1):28–48.
   PubMed Web of Science ®Google Scholar
• Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol. 1999;17(7):2180–2189.
   PubMed Web of Science ®Google Scholar
• Sun K, Xu Y, Zhang L, et al. A Phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer. Clin Cancer Res. 2022;28(20):4392–4401.
   PubMed Web of Science ®Google Scholar